genomic and epigenomic analysis in inflammatory bowel disease for investigation of pathogenes and mechanism of resistance to anti-TNF therapy.

genomic and epigenomic analysis in inflammatory bowel disease for investigation of pathogenes and mechanism of resistance to anti-TNF therapy. - genomic analysis in inflammatory bowel disease for investigation of the mechanisms of resistance to anti-TNF therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006681

Enrollment

Registered

2011-11-07

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients with Crohn's disease and ulcerative colitis who are received anti-TNFa antibody therapy

Exclusion criteria

Exclusion criteria: the patients that we cannot obtain the agreement (by IC form) about this study.

Design outcomes

Primary

Measure	Time frame
genomic factor for resistance in anti-TNFa antibody	—

Countries

Japan

Contacts

Public ContactTadakazu Hisamatsu

School of Medicine, Keio University Div. of Gastroenterology and hepatology, Dep. of Internal Medicine,

hisamachi@a7.keio.jp03-3353-1211

Outcome results